Laxmi Dental reported a 23.8% year-on-year increase in consolidated net profit to ₹103.15 million for the quarter ended June 30, 2026 (Q1FY27), driven by significant growth in its aligners business segment. The Mumbai-based dental products manufacturer saw consolidated revenue from operations rise 13.6% to ₹729.91 million, reflecting strong demand across its product lines. This financial performance was approved by the Board of Directors at a meeting held on August 11, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The statutory auditors, MSKA & Associates LLP, conducted a limited review of the unaudited standalone and consolidated financial results under Standard on Review Engagements (SRE) 2410. The audit firm issued an unmodified opinion on the statements, which were prepared in accordance with Indian Accounting Standard 34 ('Interim Financial Reporting'). The Board also noted the execution of a Letter of Intent for the proposed acquisition of land situated at Palghar, Maharashtra, for a total consideration of ₹6.21 crore, aimed at expanding business operations through factory construction.

Financial Performance Highlights

The company’s top-line growth was supported by both its core laboratory business and its expanding aligners division. While the laboratory business revenue declined slightly quarter-on-quarter, the aligners business showed substantial momentum. Key financial metrics for the quarter are detailed below:

Consolidated profit before tax increased 25.5% to ₹120.41 million from ₹95.95 million in the corresponding period last year. Other income contributed ₹22.98 million, up from ₹17.22 million previously. Total expenses stood at ₹649.53 million, compared to ₹577.24 million in Q1FY26, primarily due to higher employee benefit expenses and purchases of stock-in-trade.

Segment-Wise Analysis

The Chief Operational Decision Maker monitors performance across three segments: Laboratory Business, Aligners Business, and Other Business. The Aligners Business emerged as the primary growth engine, with revenue surging 29.1% year-on-year to ₹241.69 million. In contrast, the Laboratory Business, which remains the largest contributor, saw revenue decline 7.9% to ₹502.81 million.

The Aligners Business segment result improved dramatically to ₹65.33 million from ₹22.79 million in Q1FY26, highlighting operational leverage in this high-growth category. The Laboratory Business segment result was ₹76.98 million, down from ₹101.54 million in the prior year period.

What the Numbers Show

A notable divergence exists between revenue trends and profitability drivers across segments. While the Laboratory Business generated higher absolute revenue, its contribution to segment profit decreased significantly. Conversely, the Aligners Business, though smaller in revenue scale, delivered a disproportionate boost to overall profitability, with segment results nearly tripling year-on-year. This shift suggests an improving margin profile in the aligners division, potentially offsetting softness in the traditional laboratory products.

Corporate Developments and IPO Utilization

Beyond financial results, the Board approved the allotment of 59,360 equity shares to eligible employees upon exercise of options vested under the Laxmi Dental Stock Option Scheme 2024. The paid-up equity share capital increased from 5,49,62,149 shares to 5,50,21,509 shares. Additionally, the Board took note of the surrender of 1,636 employee stock options by Mr. Ansari Mohammed Saad, Senior Executive Technical Support.

Regarding capital allocation, the company has utilized ₹779.72 million of its initial public offer proceeds as of June 30, 2026, against a total requirement of ₹1,281.70 million. The unutilized amount of ₹501.98 million is temporarily invested in fixed deposits with banks. The company is currently seeking an extension for the utilization of these IPO proceeds in subsequent periods. The Board also reaffirmed the Scheme of Merger involving wholly-owned subsidiary Bizdent Devices Private Limited, which awaits requisite statutory approvals.

Laxmi Dental will host its Q1FY27 earnings conference call on Wednesday, August 12, 2026, at 11:00 AM IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The company disclosed the schedule pursuant to Regulation 30(6) read with Schedule III Part A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call aims to provide clarity on the operational and financial performance of the entity for the initial quarter of the fiscal year.

The announcement was filed with the Listing Department of BSE Limited and the Listing & Compliance Department of National Stock Exchange of India Limited on August 7, 2026. Suman Saha, Company Secretary and Compliance Officer, signed the intimation, confirming that the details are also available on the company’s website.

Key Participants

The following executives are scheduled to participate in the conference call:

• Rajesh Khakhar, Chairperson and Whole-Time Director
• Sameer Merchant, Managing Director and Chief Executive Officer
• Dharmesh Dattani, Chief Financial Officer

Call Access Details

Investors and analysts can join the call via the pre-registration link provided by the company or through the listed access numbers. The contact details for the call are as follows:

Strategic Growth Advisors Pvt. Ltd., represented by Dharmik Kansara and Shikha Puri, is managing the RSVP process for the event.